Cannatrek has signed a Memorandum of Understanding (MoU) with Japan’s Mie University to accelerate medical research into the use of cannabis. 

The firm said the partnership marks the first-ever MoU for medicinal cannabis research between Australia and Japan.

It follows the Japanese government’s recent change in stance towards cannabis with the lower house passing a bill to legalise medicinal use late last year.

Cannatrek CEO Tommy Huppert and MIE University director Imanishi Nobuyuki

Cannatrek CEO Tommy Huppert said: “We are honoured to be the first Australian business to have a MoU for medicinal cannabis research with a Japanese organisation.

Cannatrek’s Shepparton, Victoria facility recently received Good Manufacturing Practice (GMP) accreditation, which Huppert said would further enhance the company’s export opportunities.

The framework for cooperation under the MoU encompasses agronomic research, training resources for clinicians, pharmaceutical supply chain, e-healthcare, navigating regulation and compliance and connecting experts in the field.

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...

Leave a comment